军事知识服务平台
失效模式和效应分析应用于静脉用药调配中心风险管理的范围综述
Application of failure mode and effects analysis in risk management of pharmacy intravenous admixture services:a scoping review
摘要 目的 系统梳理失效模式和效应分析(FMEA)在静脉用药调配中心(PIVAS)中的应用范围、关键成效及现存挑战,以整合证据并为实践与研究提供参考.方法 采用范围综述方法,检索中国知网(CNKI)、万方数据(WanFang Data)、维普数据库(VIP)、中国生物医学文献数据库(SinoMed)、PubMed、Embase、Web of Science核心合集等数据库,检索时间为建库至2026年7月31日.纳入以FMEA应用于PIVAS为主题的原始研究,并提取相关数据进行描述性整合与分析.结果 共纳入58篇文献.FMEA在PIVAS中的应用领域主要涵盖全流程优化、高风险药品专项管理及特定环节精准干预.方法学上以传统FMEA与医疗失效模式和效应分析(HFMEA)为主.所有研究均报告了积极效果,包括风险优先数显著下降、调配差错率和不合理医嘱率的降低,以及工作效率的提升.但目前方法学缺乏标准,存在异质性,且有诸多挑战,包括风险评分依赖主观经验、难以处理失效模式间的关联风险、缺乏动态追踪能力以及长期效果与成本效益研究不足.结论 FMEA在PIVAS风险管理中具有明确的应用价值,可有效识别风险、优化流程、提升用药安全.未来需重点推进方法学标准化建设、控制主观偏倚、探索动态化升级路径并开展长期效益评估,促进其科学可持续应用.
Abstract:
Objective To systematically review the scope of application,key outcomes,and existing challenges of Failure Mode And Effects Analysis(FMEA)in pharmacy intravenous admixture services(PIVAS),and to consolidate the evidence and provide references for practice and research.Methods A scoping review methodology was employed.Chinese and English databases,including China National Knowledge Infrastructure(CNKI),WanFang Data,VIP,SinoMed,PubMed,Embase,and the Web of Science Core Collection,were systematically searched from database inception to July 31,2026.Original studies focusing on the application of FMEA in PIVAS were included,and relevant data were extracted for descriptive synthesis and analysis.Results A total of 58 studies were included.FMEA in PIVAS primarily encompassed overall process optimization,specialized management of high-risk medications,and targeted interventions for specific workflow segments.Methodologically,traditional FMEA and Healthcare Failure Mode And Effects Analysis(HFMEA)were predominant.All studies reported positive outcomes,including a significant reduction in the Risk Priority Number,decreased rates of compounding errors and irrational medical orders,and improved operational efficiency.However,considerable methodological heterogeneity and a lack of standardized procedures were observed.Major challenges included reliance on subjective experience in risk scoring,inability to handle inter-failure mode correlations,lack of dynamic tracking capability,and insufficient research on regarding long-term effectiveness and cost-effectiveness.Conclusion FMEA has clear application value in PIVAS risk management,can effectively identify risks and optimize workflows,and improve medication safety.Future efforts should prioritize methodological standardization,subjective bias control,dynamic upgrading exploration,and long-term benefit evaluation to promote its scientific and sustainable application.
刊 名 药学前沿
年,卷(期): 2026, 30(9)
分类号: R95
机标分类号: R952 O657.3 R457.1
在线出版日期: 2026年10月16日
基金项目: YLZLXZ23K004:国家卫生健康委医院管理研究所医疗质量(循证)管理研究项目,